149 related articles for article (PubMed ID: 37726298)
1. In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Rifkin RM; Girnius SK; Noga SJ; Birhiray RE; Kambhampati S; Manda S; Lyons RM; Yimer HA; Cherepanov D; Lloyd E; Whidden P; Richter J
Blood Cancer J; 2023 Sep; 13(1):147. PubMed ID: 37726298
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
[TBL] [Abstract][Full Text] [Related]
3. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
5.
Rifkin RM; Costello CL; Birhiray RE; Kambhampati S; Richter J; Abonour R; Lee HC; Stokes M; Ren K; Stull DM; Cherepanov D; Bogard K; Noga SJ; Girnius S
Future Oncol; 2024 Jan; 20(3):131-143. PubMed ID: 37807952
[No Abstract] [Full Text] [Related]
6. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
7. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Minarik J; Radocha J; Jungova A; Straub J; Jelinek T; Pika T; Pour L; Pavlicek P; Harvanova L; Pospisilova L; Krhovska P; Novakova D; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Maisnar V; Hajek R
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291949
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
14. Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L; Wang YT; Liu P; Lu MQ; Zhuang JL; Zhang M; Xia ZJ; Li ZL; Yang Y; Yan ZY; Jing HM; Dong F; Chen WM; Wu Y; Zhou HB; Fu R; Gong YP; Huang WR; Zhang YQ
EClinicalMedicine; 2024 Feb; 68():102431. PubMed ID: 38318126
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Abe Y; Sasaki M; Takezako N; Ito S; Suzuki K; Handa H; Chou T; Yoshida T; Mori I; Shinozaki T; Suzuki K
Ann Hematol; 2023 Sep; 102(9):2493-2504. PubMed ID: 37341778
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone.
Huo Z; Chen F; Liu P; Luo Z
Cancer Med; 2023 Feb; 12(3):2937-2944. PubMed ID: 36052569
[TBL] [Abstract][Full Text] [Related]
18. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK; Laubach JP; Yee AJ; Chen T; Huff CA; Basile FG; Wade PM; Paba-Prada CE; Ghobrial IM; Schlossman RL; Burke JN; Harrington CC; Lively KJ; Lyons HF; Munshi NC; Anderson KC; Trippa L; Richardson PG; Raje NS
Br J Haematol; 2018 Jul; 182(2):222-230. PubMed ID: 29740809
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
